The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Requip 0.25 mg film-coated tablets

0.25 milligram(s) Film-coated tablet

GlaxoSmithKline (Ireland) LimitedPA1077/037/001

Main Information

Trade NameRequip 0.25 mg film-coated tablets
Active SubstancesRopinirole hydrochloride
Strength0.25 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/037/001

Group Information

ATC CodeN04BC Dopamine agonists
N04BC04 ropinirole

Status

Authorised/WithdrawnAuthorised
Licence Issued03/12/1996
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back